GENFIT engage un programme de développement clinique de phase 2 avec Nangibotide dans l’ACLF
Filed with Euronext · · 4 pages · French
Earlier from Genfit
- GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
- GENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- GENFIT annonce sa participation à la H.C. Wainwright 28th Annual Conference
- GENFIT présente le potentiel commercial à long terme de sa technologie de diagnostic dans la MASH
- GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026
Later from Genfit
- GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF
- Genfit: Résultats financiers du premier semestre 2026 et point sur les activités de la Société
- GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
- GENFIT to Highlight Progress in ACLF and MASH Diagnostics at AASLD The Liver Meeting® 2026
- GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update
Follow Genfit into a list and get an email when it puts out news.
Follow Genfit